Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessia Filippone

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Cancers|August 26, 2022
Adenosine Targeting as a New Strategy to Decrease Glioblastoma AggressivenessValentina Bova, Alessia Filippone, Giovanna Casili, et al.
Pharmaceuticals (Basel, Switzerland)|August 29, 2024
EZH2 Inhibition to Counteract Oral Cancer Progression through Wnt/β-Catenin Pathway ModulationMichela Campolo, Sarah Adriana Scuderi, Alessia Filippone, et al.
Cancers|June 22, 2023
Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC)Giovanna Casili, Sarah Adriana Scuderi, Marika Lanza, et al.
Cancers|March 28, 2024
Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). <i>Cancers</i> 2023, <i>15</i>, 2796Giovanna Casili, Sarah Adriana Scuderi, Marika Lanza, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Cancers|August 26, 2022
Adenosine Targeting as a New Strategy to Decrease Glioblastoma AggressivenessValentina Bova, Alessia Filippone, Giovanna Casili, et al.
Pharmaceuticals (Basel, Switzerland)|August 29, 2024
EZH2 Inhibition to Counteract Oral Cancer Progression through Wnt/β-Catenin Pathway ModulationMichela Campolo, Sarah Adriana Scuderi, Alessia Filippone, et al.
Cancers|June 22, 2023
Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC)Giovanna Casili, Sarah Adriana Scuderi, Marika Lanza, et al.
Cancers|March 28, 2024
Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). <i>Cancers</i> 2023, <i>15</i>, 2796Giovanna Casili, Sarah Adriana Scuderi, Marika Lanza, et al.
Pageof 8